42nd Meeting of the Physicians - Opening Session Highlights
32nd Meeting of the Nurses Group
15th Meeting of the Data Management Group
10th Patient, Family and Donor Day
8th Meeting of the Quality Management Group
5th Cell Therapy Day
5th Paediatric Day
1st Pharmacist Day
video to hear from the Van Bekkum and Basic Science Awards Winners, as well as the guest lecturer Jesús San Miguel who gave the EBMT lecture on "Multiple Myeloma: Evolution in the treatment landscape".
The main conference was attended by 503 nurses (more than 300 non-members) from 46 countries. The programme focused on management of transplant complications and patients’ expectations.
The Key Note Speaker for the Opening Lecture was Arno Mark from The Netherlands who spoke about the “Evolution of the Transplant Nurse”.
There were new features in the Nurses Group Scientific Program including:
One session was dedicated to the collaborative project between EBMT/ MASCC (Multinational Association of Supportive Care in Cancer)/ ISOO (International Society of Oral Oncology) and focused on the management of oral complication, oral GvHD and other late complications.
The multi-disciplinary joint session with physicians was about the role of palliative care in SCT.
Link:EBMT-TV - The importance of patient care - Education Day
Integrating Patient Care into EBMT with Aleksandra Babic
The clinical education sessions included: Cell therapy; Conditioning for allos; Donor outcome follow up; Inherited disorders; Burning issues regarding de novo and secondary AML classification; Cord Blood; The Co-morbidity index; Ex vivo manipulation and Case Studies on evaluating response to treatment and relapse in Myeloma.
There were also some general sessions regarding: Performing a study; JACIE – the process explained; Optimising data collection at a BMT unit; and an interactive session regarding the Changes to the Med-A form. The ProMISe Database Training sessions were once again very well attended. Data Management and Statistics posters were displayed in the poster hall. Many Data Managers and colleagues enjoyed the evening reception event.
Thank you to all our presenters and to everyone who attended. Suggestions for the Data Management Programme next year in Marseille are welcome - please email: email@example.com. The slide presentations & feedback report will be available on the website shortly. We look forward to seeing as many Data Managers as possible in France next year!
The event had been carefully orchestrated by a team of nurses, doctors, social workers, caregivers, teachers, patients, donors, relatives and patient associations. This day offered a great chance to learn from each other about the latest research outcomes in the field of blood and marrow transplantation, and show gratitude to all the donors. The event concluded with personal experiences of two transplanted patients. One of them was Maarten van der Weijden from the Netherlands, who told his amazing story. Maarten is a leukaemia survivor (2001) who went on to win a gold medal at the 2008 Olympic Games in Beijing for marathon swimming in open water.
An Olympian and Patient Advocate - Maarten van der Weijden
The most important person in Blood and Marrow Transplantation - Patient, Family & Donor Day
For the first time, there was a JACIE session outside of the traditional Tuesday programme which opened the topic to a new audience attending the Cell Processing Day. JACIE was also present at the WBMT-EBMT Joint Session where the First-Step project was explained, included in the programme for the Pharmacist Day sessions and featured as a special talk for Data Managers.
The Tuesday programme featured a Quick Fire session where 7 talks on diverse but related topics meant that the audience was opened to different points of view around quality, standards, accreditation and healthcare. Listeners heard about the most common issues identified during inspections under the 5th edition, an important question in terms of learning from the experience of others, and discovered the latest focus of research in the field of quality and healthcare.
As always, we enjoyed the chance to see and talk to old friends and make new ones from all over the world. These encounters keep our feet on the ground and are our favourite way to know what is happening at the front line of quality and transplantation.
Finally, thank you to all our speakers and chairs who make the meeting possible. We are truly honoured to have you with us and sharing your expertise and knowledge.
For Marseille 2017, we are already thinking about the programme and would be very happy to hear from readers with their ideas for subjects or formats. Also, keep in mind that we are very keen to see original research included in the Quality Management programme next year and so strongly urge you to think about practice in your centre, audits that you performed and associated corrective actions that would be of interest to a wider audience. We have seen centres in different countries grapple with almost identical challenges and therefore your experience will very probably resonate with colleagues in other transplant programmes. So have a think and watch out for the Abstracts announcement after the summer.
Link:EBMT-TV - JACIE - Joint Accreditation Committee for ISCT & EBMT
It included 4 sessions with 4 speakers each, the last session being concluded by the incoming ISCT President, Catherine Bollard, who provided a US view of new developments in cellular therapies focusing on CAR-T Cells. Dr Bollard offered a counterpoint to the European perspective.
The fours sessions followed a logical progression to illustrate how – in an era that may represent an landmark transition in the history of medicine - we are moving from “cell transplants” to “cellular therapies”, designed to take advantage of our ever-expanding technological capacities in cell and gene engineering. While processing of minimally-manipulated cell products is still undergoing significant improvements in cell collection and cell processing facilities that locally serve the needs of transplant programmes, in part to comply with FACT-JACIE standards as well as other regulatory requirements, we now witness the emergence of far more advanced cellular therapies that will be manufactured by industry, similarly to chemical medicinal products or other biologics: this not only represents a medical and biological challenge, but also an organizational, financial and ethical challenge since it will disrupt our historical organization for the delivery of hematopoietic stem cell transplantation. How these two fields will coexist in the near future will be under intense scrutiny from our community.
EBMT-TV - Cell Therapy Day with Chiara Bonini & Christian Chabannon
The Paediatric Day at EBMT is a good way to acknowledge the progress we are making in treating and curing children. One major focus was laid on cellular- immunotherapy as this topic is currently revolutionize the field. So, highlights from the morning were the latest stunning results from the TCRalpha/beta depletion studies with suicide gene T cell add-back, new methods of manipulating mesenchymal stromal cells to give a consistent MSC product, as well as updates on gene therapy for primary immunodeficiency, metabolic diseases and haemoglobinopathies. It was impressive to see how the pediatric science influence and drive current developments in stem cell transplantation and immunotherapy.
Many interesting abstracts presenting new data completed a busy day during the afternoon sessions. Of note this year, three of the abstracts presented at the Presidential symposium were addressing paediatric diseases. The networking remains an important part of the Paediatric Day - to discuss difficult cases, develop projects and meet friends. For trainees, the opportunity to present data and discuss with experts in the field is invaluable.
All sessions have been very well attended and all the educational events were fully booked. There are any exciting new developments in paediatric transplantation and this years Paediatric Day was an excellent place to learn about these.
Link:EBMT-TV - Paediatrics Day with Andrew Gennery and Peter Bader
The sessions were very educational and included presentations on: Drug dosing and monitoring in obese patients, busulfan, immunosuppressive therapy and anti-fungal therapy dosing. The pharmacists’ perspective in SCT, JACIE for Pharmacist, Orphan drugs in allogeneic SCT, Stem cells mobilization update and Resistance to antibiotics. Side effects of novel therapies such as Blinatumomab, Ibrutinib and Idelalisib, Brentuximab and Nivolumab, and JAK2 inhibitors. What a pharmacist should know about antiemetic therapy, drug interactions, nutrition and adherence and information to patient. Other practical issues such as The pharmacist and drug shortage, Drug-related problems and Outpatient SCT.
All the participants had the opportunity to gain updated and practical information from the excellent presentations and could ask questions that enriched the discussion. We are very proud to know that this new initiative will continue next year as the Second Pharmacist Day.
EBMT-TV - The Pharmacist Day with Irene Mangues and Estela Moreno Martinez